KZIA

Kazia Therapeutics Limited is an oncology-focused biotechnology company developing innovative cancer treatments. The company's lead programs include paxalisib, a brain-penetrant PI3K inhibitor being studied for brain cancers including glioblastoma, and EVT801, a VEGFR3 inhibitor in development for various solid tumors. Kazia focuses on addressing high unmet medical needs in difficult-to-treat cancers with limited therapeutic options.